Trial Profile
Randomized, Open-Label, Comparative Safety and Efficacy Study of Tipranavir Boosted With Low-Dose Ritonavir (TPV/RTV) Verses Genotypically-Defined Protease Inhibitor/Ritonvair (PI/RTV) in Multiple Antiretroviral Drug-Experienced Patients.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Tipranavir (Primary) ; HIV protease inhibitors; Ritonavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms RESIST-1
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 02 Jun 2009 Additional trial locations (Canada and Australia) identified as reported by ClinicalTrials.gov.
- 12 Nov 2008 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
- 06 Oct 2008 Planned end date changed from 1 Mar 2009 to 1 Sep 2009, based on information from ClinicalTrials.gov.